Rare Biomarkers Specimen Collection And Stabilization Global Market Report 2024

The rare biomarkers specimen collection and stabilization market size has grown rapidly in recent years. It will grow from $29.02 billion in 2023 to $32.01 billion in 2024 at a compound annual growth rate (CAGR) of 10.3%. The growth during the historic period can be attributed to several factors, the Human Genome Project, an increase in cancer research, investment in pharmaceutical R&D, the expansion of genomics and proteomics, and advancements in data management and bioinformatics.

The rare biomarkers specimen collection and stabilization market size is expected to see rapid growth in the next few years. It will grow to $47.59 billion in 2028 at a compound annual growth rate (CAGR) of 10.4%. The growth in the forecast period can be attributed to the expansion of liquid biopsy applications, increased consumer awareness and demand, greater adoption of non-invasive techniques, and biomarker discovery in rare diseases. Major trends during this period include advancements in preservation technology, growth in genomic and proteomic research, the emergence of point-of-care testing, regulatory advancements and standardization, and enhanced data analytics with AI integration.

The increasing prevalence of cancer is expected to propel the growth of the rare biomarker specimen collection and stabilization market. Cancer, characterized by the uncontrolled proliferation and spread of abnormal cells, is rising in prevalence due to environmental pollutants and lifestyle factors, such as smoking and poor diet choices, which exacerbate genetic predispositions. The utilization of rare biomarker specimen collection and stabilization methods in cancer prevalence studies facilitates more accurate detection and monitoring of specific cancer types, thereby enhancing diagnostic and therapeutic approaches. For example, in October 2023, a report by the European Commission, a Europe-based governing body, indicated that new cancer cases rose to 2.74 million in 2022, reflecting a 2.3% increase from 2020. Consequently, the increasing prevalence of cancer is driving the growth of the rare biomarker specimen collection and stabilization market.

Major companies in the rare biomarker specimen collection and stabilization market are focusing on developing innovative solutions, such as pre-analytical platforms to automate the preparation of plasma and cell samples for multiomic liquid biopsy. Pre-analytical platforms provide consistent, automated fresh sample preparation at the time of blood collection, allowing for complete walk-away processing of whole blood without the need for special tubes or skilled professionals, thus preserving sample integrity. For instance, in May 2022, Tethis S.p.A., an Italy-based biotechnology company, launched See.d, the first fully automated, standardized pre-analytical platform offering unique features such as precise sample handling, efficient separation of plasma for cellular fractions, and fixation of white blood cells on SmartBioSurface slides. The platform includes a quality control scoring system for objectively evaluating sample stability, enabling the systematic scoring of proteomics and metabolomics data sets to determine the stability of plasma and serum samples.

In October 2022, DiaSorin, an Italy-based biotechnology company, acquired Luminex Corporation for an undisclosed amount. With this acquisition, DiaSorin aims to leverage multiplexing technology and Luminex's portfolio to strengthen its existing offerings. This acquisition aims to enhance DiaSorin's diagnostic testing capabilities, expand its market presence, and drive innovation in the molecular and immunodiagnostics sectors. Luminex Corporation is a US-based provider of proprietary biological testing instruments involving rare biomarker specimen collection and stabilization.

Major companies operating in the rare biomarkers specimen collection and stabilization market are F. Hoffmann-La Roche AG, Thermo Fisher Scientific Inc., Abbott Laboratories, Merck KGaA, Becton Dickinson and Company, Eurofins Scientific SE, Agilent Technologies Inc., PerkinElmer Inc., Illumina Inc., Charles River Laboratories International Inc., Bio-Rad Laboratories Inc., Bruker Corporation, QIAGEN N.V., Miltenyi Biotec GmbH, Natera Inc., Promega Corporation, Myriad Genetics, Hamilton Company, OraSure Technologies Inc., Fluidigm Corporation, Streck Inc., SeraCare, Enzo Biochem Inc., Epigenomics AG, Veridex LLC.

North America was the largest region in the rare biomarkers specimen collection and stabilization market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the rare biomarkers specimen collection and stabilization market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the rare biomarkers specimen collection and stabilization market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Rare biomarkers specimen collection and stabilization involves the process of gathering and preserving biological samples that contain rare or low-abundance molecules, which indicate specific biological processes, diseases, or conditions. These biomarkers can include specific proteins, nucleic acids, metabolites, or other substances. The goal of collecting and preserving these rare biomarkers is to allow for accurate and reliable measurement and analysis for diagnostic, prognostic, and therapeutic purposes.

The primary types of rare biomarker specimen collection and stabilization include circulating cell-free DNA (ccFDNA), circulating tumor cells (CTCs), exosomes, and extracellular vesicles. Circulating cell-free DNA (ccFDNA) consists of DNA fragments freely circulating in the bloodstream, originating from both healthy and diseased cells. These fragments carry genetic information and can be analyzed for various diagnostic purposes, such as cancer detection or monitoring treatment effectiveness. Various specimens, such as serum or plasma, are used for applications including non-invasive prenatal testing (NIPT), oncology, transcriptomics, pharmacogenomics, transplant rejection, population screening, cardiovascular diseases, and others. These specimens are utilized by a range of end-users, including hospitals, perinatal clinics, public health labs, private or commercial labs, physician labs, research institutes, and others.

The rare biomarkers specimen collection and stabilization market research report is one of a series of new reports that provides rare biomarkers specimen collection and stabilization market statistics, including the rare biomarkers specimen collection and stabilization industry global market size, regional shares, competitors with rare biomarkers specimen collection and stabilization market share, detailed rare biomarkers specimen collection and stabilization market segments, market trends, and opportunities, and any further data you may need to thrive in the rare biomarkers specimen collection and stabilization industry. These rare biomarkers specimen collection and stabilization market research reports deliver a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The rare biomarkers specimen collection and stabilization market consists of revenues earned by entities by providing services such as sample collection, stabilization and preservation, customized collection protocols, bio banking and storage and data management and reporting. The market value includes the value of related goods sold by the service provider or included within the service offering. The rare biomarkers specimen collection and stabilization market also includes sales of biomarker collection kits, laboratory equipment, training and educational materials, quality control materials, and sample storage containers. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.